{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:14:11Z","timestamp":1747167251116,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.mbs.2015.01.011","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T12:40:22Z","timestamp":1422967222000},"page":"117-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations"],"prefix":"10.1016","volume":"262","author":[{"given":"Dana","family":"Paquin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-7174","authenticated-orcid":false,"given":"John","family":"Shamshoian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mbs.2015.01.011_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00001622-200403000-00002","article-title":"Treatment options for chronic myelogenous leukemia: imatinib versus interferon versus allogeneic transplant","volume":"16","author":"Angstreich","year":"2004","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/j.mbs.2015.01.011_bib0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1006\/jtbi.2003.3208","volume":"221","author":"Antia","year":"2003","journal-title":"J. Theor. Biol."},{"issue":"11","key":"10.1016\/j.mbs.2015.01.011_bib0003","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.mbs.2015.01.011_bib0004","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.mbs.2015.01.011_bib0005","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.171.8.3928","article-title":"Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection","volume":"171","author":"DeBoer","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.mbs.2015.01.011_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000095","article-title":"Dynamics and potential impact of the immune response to chronic myelogenous leukemia","volume":"4","author":"Kim","year":"2008","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mbs.2015.01.011_bib0007","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: principles of emergence and prevention","volume":"102","author":"Komarova","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mbs.2015.01.011_bib0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1365-2141.2000.02216.x","article-title":"Chronic myelogenous leukemia","volume":"111","author":"Lee","year":"2000","journal-title":"Br. J. Hematol."},{"key":"10.1016\/j.mbs.2015.01.011_bib0009","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia","volume":"349","author":"Lowenberg","year":"2003","journal-title":"New England J. Med."},{"key":"10.1016\/j.mbs.2015.01.011_bib0010","first-page":"239","article-title":"A comparison of three models for selecting values of input variables in the analysis of output from a computer code","volume":"21","author":"McKay","year":"1979","journal-title":"Technometrics"},{"key":"10.1016\/j.mbs.2015.01.011_bib0011","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mbs.2015.01.011_bib0012","first-page":"1082","article-title":"Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia","author":"Paquin","year":"2011","journal-title":"73"},{"key":"10.1016\/j.mbs.2015.01.011_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-007-0241-y","article-title":"Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia\u2013insights from mathematical model analyses","volume":"86","author":"Roeder","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.mbs.2015.01.011_bib0014","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical applications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.mbs.2015.01.011_bib0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","article-title":"Do we have to kill the last CML cell","volume":"25","author":"Ross","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.mbs.2015.01.011_bib0016","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"2000","journal-title":"New England J. Med."},{"key":"10.1016\/j.mbs.2015.01.011_bib0017","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mbs.2015.01.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028955","article-title":"Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data","volume":"6","author":"Werner","year":"2011","journal-title":"PLoS One"}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556415000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556415000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T09:56:45Z","timestamp":1537869405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556415000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":18,"alternative-id":["S0025556415000309"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2015.01.011","relation":{},"ISSN":["0025-5564"],"issn-type":[{"type":"print","value":"0025-5564"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2015.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}